Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California.
Parker Institute for Cancer Immunotherapy, San Francisco, California.
Cancer Immunol Res. 2023 Aug 3;11(8):1030-1043. doi: 10.1158/2326-6066.CIR-22-0962.
The immune system includes an array of specialized cells that keep us healthy by responding to pathogenic cues. Investigations into the mechanisms behind immune cell behavior have led to the development of powerful immunotherapies, including chimeric-antigen receptor (CAR) T cells. Although CAR T cells have demonstrated efficacy in treating blood cancers, issues regarding their safety and potency have hindered the use of immunotherapies in a wider spectrum of diseases. Efforts to integrate developments in synthetic biology into immunotherapy have led to several advancements with the potential to expand the range of treatable diseases, fine-tune the desired immune response, and improve therapeutic cell potency. Here, we examine current synthetic biology advances that aim to improve on existing technologies and discuss the promise of the next generation of engineered immune cell therapies.
免疫系统包括一系列专门的细胞,通过对病原体信号做出反应来保持我们的健康。对免疫细胞行为背后的机制的研究导致了强大的免疫疗法的发展,包括嵌合抗原受体 (CAR) T 细胞。尽管 CAR T 细胞已被证明在治疗血液癌方面有效,但关于其安全性和效力的问题限制了免疫疗法在更广泛疾病谱中的应用。将合成生物学的进展整合到免疫疗法中的努力带来了几项进展,这些进展有可能扩大可治疗疾病的范围、微调所需的免疫反应并提高治疗细胞的效力。在这里,我们检查了旨在改进现有技术的当前合成生物学进展,并讨论了下一代工程免疫细胞疗法的前景。